Effects of donor plasma and recipient characteristics on convalescent plasma treatment outcome of COVID-19

在缺乏FDA批准的药物治疗的情况下，恢复期血浆输注已迅速成为COVID-19重症病例的一种值得注意的紧急治疗方法。然而，由于这种治疗是在紧急情况下进行的，因此在表征供体血浆的性质和最能从输注中受益的COVID- 19患者的临床状态方面几乎没有付出任何努力。我们组建了一个多学科团队，利用罗伯特·伍德约翰逊大学医院的献血和输血项目以及最先进的资源，研究COVID-19严重程度的抗体反应和血浆标志物。该团队建议进行一项研究，将供体血浆特性（抗体滴度和功能，以及抗原靶点）和受体的临床状态（包括外周血细胞免疫表型和COVID-19严重程度的各种血浆标志物）与恢复期血浆输注的成功联系起来。从我们的计划中获得的新知识将指导合理的临床实践指南的制定和恢复期血浆临床试验的设计。

In the absence of FDA-approved pharmacological therapies, convalescent plasma infusion has rapidly emerged as a notable emergency therapy for severe cases of COVID-19. However, due to the emergency conditions under which this treatment has been practiced, little effort has been placed in characterizing the properties of the donor plasma and the clinical status of the COVID- 19 patients that can most benefit from the infusion. We have assembled a multidisciplinary team that leverages linked blood donation and blood transfusion programs at Robert Wood Johnson University Hospital and state-of-the-art resources for the study of antibody responses and plasma markers of COVID-19 severity. This team proposes to conduct a study that relates donor plasma properties (antibody titers and functions, and antigen targets) and recipient's clinical status (including peripheral blood cell immunophenotypes and various plasma markers of COVID-19 severity) to the success of convalescent plasma infusion. The new knowledge resulting from our plan will guide the development of rational clinical practice guidelines and the design of convalescent plasma clinical trials.